Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438520 | 0.90 | GRIK1 (0.81) | GRIK1MEN1KMT2A | |
| SCHEMBL1462231 | 0.84 | GRIK1 (0.72) | GRIK1MEN1KMT2A | |
| SCHEMBL1462989 | 0.84 | GRIK1 (0.72) | GRIK1MEN1KMT2A | |
| SCHEMBL1462967 | 0.82 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL4837100 | 0.81 | GRIK1 (0.68) | GRIK1MEN1KMT2A | |
| SCHEMBL6430799 | 0.81 | GRIK1 (0.72) | GRIK1MEN1KMT2AGRIK2 | |
| SCHEMBL27546650 | 0.81 | GRIK1 (0.67) | GRIK1MEN1KMT2A | |
| SCHEMBL3961542 | 0.81 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL27519972 | 0.81 | GRIK1 (0.67) | GRIK1MEN1KMT2A | |
| SCHEMBL3957527 | 0.80 | GRIK1 (1.00) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | claimed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | claimed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | claimed |
| US-7521480-B2 | Aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2009-04-21 | — | — | US | disclosed |
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | GABRA5, GRIK5, GRM5 | GRIK1 24/4885MEN1 4843/4885KMT2A 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.